Treats moderate-to-severe plaque psoriasis. Sold as Sotyktu. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Deucravacitinib (sold as Sotyktu), first approved Sep 9, 2022, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Sotyktu | Part D | $126M | +102% | 2,983 |
| Comparison of Efficacy and Safety of Deucravacitinib Versus Methotrexate in the Treatment of Moderate-to-Severe Plaque Psoriasis .Psoriasis · Bangladesh Medical University | Phase 4 | Active, not recruiting | Nov 4, 2026 |
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study CompletersSystemic Lupus Erythematosus, Sjögren's Disease · Bristol-Myers Squibb | Phase 3 | Not yet recruiting | Aug 27, 2026 |
| A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque PsoriasisPsoriasis · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 3 | Recruiting | Jul 24, 2026 |
| Deucravacitinib in the Treatment of Cicatricial AlopeciasCentral Centrifugal Cicatricial Alopecia, Frontal Fibrosing Alopecia · Icahn School of Medicine at Mount Sinai | Phase 2 | Recruiting | Apr 2, 2026 |
| Utilization of a Microdevice for Psoriasis and Atopic DermatitisPsoriasis, Atopic Dermatitis · University of California, San Francisco | Phase 4 | Not yet recruiting | Jan 20, 2026 |
| A Study of BMS986365 in Combination With Degarelix in People With Prostate CancerProstate Cancer · Memorial Sloan Kettering Cancer Center | Phase 2 | Active, not recruiting | Jan 13, 2026 |
| A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque PsoriasisPlaque Psoriasis · InventisBio Co., Ltd | Phase 3 | Recruiting | Jan 8, 2026 |
| Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic DiseasePsoriatic Arthritis (PsA) · University of Texas Southwestern Medical Center | Phase 4 | Recruiting | Dec 12, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
